AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2017
Nov 3, 2017
29828_dirs_2017-11-03_b989bc85-1604-4192-8d7d-c69db300c105.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2017-11-01
Reporting Person: Alton Gregg H (EVP Comm&Acs ALA, Corp&Med Aff)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-01 | Common Stock | M | 8625 | $24.905 | Acquired | 77363 | Direct |
| 2017-11-01 | Common Stock | S | 13400 | $74.7397 | Disposed | 63963 | Direct |
| 2017-11-01 | Common Stock | S | 1600 | $75.4831 | Disposed | 62363 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-11-01 | Non-qualified Stock Option (Right to Buy) | $24.905 | M | 8625 | Disposed | 2019-07-29 | Common Stock (8625) | Direct |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
F3: Sale prices reported for the transactions reported here range from $74.22 to $75.21. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F4: Sale prices reported for the transactions reported here range from $75.25 to $75.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.